Mycobacterium bovis bacillus Calmette-Guerin (BCG) is given to millions of neonates in developing countries as a vaccine against Mycobacterium tuberculosis; however, little is known about the initiation of response in neonatal dendritic cells (DCs) to BCG. To address this issue, the interaction of BCG with human cord blood monocyte-derived DCs was studied. We showed that BCG could promote cord blood monocyte-derived DC maturation by up-regulation of CD80, CD83, CD86, CD40, and MHC class II molecules and down-regulation of mannose receptor. BCG was able to induce similar levels of tumor necrosis factor-␣ and IL-10 but no bioactive IL-12p70 production from cord blood DCs as from adult blood DCs. Functionally BCG-treated cord blood DCs had higher ability to induce mixed lymphocyte reaction than non-BCG-treated cord blood DCs. Both non-BCG-treated and BCG-treated cord blood DCs efficiently induced a high level of IL-10, medium level of interferon-␥, but little IL-4 production by cord blood naïve CD4 ϩ T cells. Heat shock protein 65, a key component of BCG, had no effect on cord blood DC maturation in terms of CD86, MHC class II, and mannose receptor up-regulation. During the BCGinduced maturation process of cord blood DCs, nuclear transcription factor Rel-B was up-regulated and cytosolic Rel-B downregulated with cytosolic IB ␣ and ␤ degradation. These results suggest that BCG can promote cord blood monocyte-derived DC maturation, and that the mechanism is through the up-regulation of nuclear Rel-B secondary to the degradation of cytosolic IB ␣ and ␤. ϩ monocytes under appropriate cytokine stimulation (2-5). Inflammatory mediators or microbial agents promote DC maturation, with up-regulation of CD80, CD83, CD86, CD40, and MHC II class molecules (6). Expression of nuclear transcription factor Rel-B correlates with activation of human DCs (7-10). Functionally, DCs are divided into myeloid DCs termed type 1 DC (DC1) and lymphoid DCs termed type 2 DC (DC2) according to their ability to polarize Th1 or Th2 development (11).
Dendritic cells (DCs) are professional antigen-presenting cells and critical initiators of primary immune response (1) . Immature DCs can be differentiated in vitro from CD34 ϩ stem cells or peripheral blood CD14 ϩ monocytes under appropriate cytokine stimulation (2) (3) (4) (5) . Inflammatory mediators or microbial agents promote DC maturation, with up-regulation of CD80, CD83, CD86, CD40, and MHC II class molecules (6) . Expression of nuclear transcription factor Rel-B correlates with activation of human DCs (7) (8) (9) (10) . Functionally, DCs are divided into myeloid DCs termed type 1 DC (DC1) and lymphoid DCs termed type 2 DC (DC2) according to their ability to polarize Th1 or Th2 development (11) .
BCG has been found to have strong nonspecific immunostimulatory properties (12) . It has been noted that interaction of human adult peripheral blood DCs with BCG results in direct maturation and activation, with up-regulation of costimulatory molecules and increases in IL-12 and proinflammatory cytokine production (13, 14) . BCG-infected DCs are more efficient than uninfected DCs in eliciting a potent T-helper 1 (Th1) response (15) . As a strong inducer for Th1 polarization, BCG has the potential to be used in the treatment of atopic asthma (16) .
Neonates are susceptible to infections because of immune deficiency, in particular Th1 deficiency, which results in the vulnerability to different intracellular pathogens such as mycobacteria and viruses (17) . The Th2 bias in newborns would impair their response to vaccines (18) . It has been suggested that the Th1 response induced by mycobacteria could prevent the development of allergen-specific Th2 response and atopy during childhood (19) . Because neonatal BCG vaccination represents one of the first infectious challenges during life, it could have a strong impact on the development of the immune system. Marchant et al. (20) found that BCG vaccination at birth induces a memory Th1-type response of similar magnitude to that when given later in life.
In our previous studies, we have reported that the proliferative response of T cells, cytokine production, and monocyte function of cord blood are significantly decreased compared with that of adult peripheral blood (21) (22) (23) . Furthermore, we found that the ability of cord blood monocytes to differentiate into CD1a ϩ dendritic cells was significantly lower than that of adult peripheral blood monocytes and speculate that the dysfunction of cord blood monocytes to differentiate into professional DCs may affect the initiation of naïve T cells, especially Th1 development, and may be related to the susceptibility of neonates to different infections in particular intracellular pathogens, such as Mycobacterium tuberculosis (24) .
We therefore investigated in this study whether BCG could promote maturation of the cord blood monocyte-derived DCs as in adults, and furthermore whether these mature monocytederived DCs could support Th1 development. In addition, we studied the role of NF-B pathway in the BCG-induced maturation of cord blood monocyte-derived dendritic cells.
METHODS

Sample collection.
Human umbilical cord blood was obtained from the placentae of normal, full-term infants, after the placentae were delivered and separated from the infants, with prior written informed consent of their mothers. All samples were collected in heparinized flasks. Adult blood was collected from normal volunteers with oral consent. The ethics committee of the University of Hong Kong approved the protocol.
Isolation of monocytes. Blood mononuclear cells were isolated from whole blood by centrifugation, using FicollHypaque gradients (Pharmacia Biotech, Uppsala, Sweden). Mononuclear cells at the interface were collected, washed three times, and resuspended at 1 ϫ 10 8 /mL, pH 7.2, Hanks/HEPES buffer. Monocytes were isolated from mononuclear cells by positive selection using anti-CD14 -conjugated magnetic microbeads (Miltenyi Biotec, Bergisch Gladbach, Germany). Isolated cells from the positive fraction were cultured at a density of 1 ϫ 10 6 cells/mL in a serum-and hormone-free medium, Dulbecco's Modified Eagle's Medium Nutrient Mixture F-12 Ham (DMEM-F12; Sigma Chemical Co, St. Louis, MO, U.S.A.), which did not contain insulin, IGF-I, or other hormones, supplemented with 50 IU/mL penicillin and 50 g/mL streptomycin. Cell viability, as measured by trypan blue exclusion, was more than 95%. The purity of monocytes was measured by flow cytometry with 85% to 95% of the cells being CD14
ϩ .
Isolation of cord blood CD3
؉ T cells and naïve CD4 ؉ T cells. Cord blood CD3
ϩ T cells were isolated from cord blood mononuclear cells by positive selection using anti-CD3-conjugated magnetic microbeads (Miltenyi Biotec). The purity of the isolated CD3 ϩ T cells was consistently within the range of 95% to 99%. CD4 ϩ naïve T cells were isolated from cord blood monocytes by CD4 ϩ T cell isolation kit (Miltenyi Biotec), with more than 90% of the isolated cells being CD4 ϩ CD45RA ϩ T cells .
Generation of immature DCs in vitro.
A total of 1 ϫ 10 6 monocytes were cultured in the presence of IL-4 (10 ng/mL; R&D Systems Inc, Minneapolis, MN, U.S.A.) and granulocyte-macrophage colony-stimulating factor (GM-CSF; 50 ng/ mL; R&D Systems Inc) for 7 d at 37°C in a humidified atmosphere containing 5% CO 2 as in our previous study (24) . The cultures were fed with fresh serum-free DMEM-F12 medium and cytokines every 3 d, and cell differentiation was monitored by light microscopy. This constituted the non-BCGtreated DC group. For the BCG-treated DC group, BCG (50 L, Danish strain 1331; Statens Serum Institute, Copenhagen S., Denmark, or Merieux Seed derived from strain 1077; Pasteur Merieux Connaught, Lyon, France) was added for the last 2 d of the culture. Dendritic cells were harvested, centrifuged, and washed before further assays.
Immunofluorescence staining. After 7 d in culture, cells were collected, transferred to microcentrifuge tubes, diluted with 1 mL PBS, and centrifuged at 13,000 ϫ g for 10 s. The supernatant was removed, and the cell pellet was resuspended in the small amount of remaining PBS. Fluorochromeconjugated antibodies at concentrations of 4 g/10 6 cells were added, and then the cell suspension was incubated for 15 min at 20°C. After incubation, the cells were diluted in 1 mL of wash solution (PBS ϩ 0.1% fetal bovine serum ϩ 0.1% azide), and after centrifugation and removal of supernatant, the cells were resuspended in 300 L of the same solution for flow cytometric analysis. FITC-, Phycoerythrin (PE)-, and Phycoerythrin-cyanin 5.1 (PC5)-conjugated isotype controls and CD14-FITC, CD80-FITC, CD83-FITC, CD86-FITC, CD40-FITC, MHC class II-FITC, CD11c-PE, MR-PE, and CD1a-PC5 were purchased from PharMingen (San Diego, CA, U.S.A.).
Signal analysis. Flow cytometric analysis was performed with a Coulter Epics Elite Flow Cytometer (Coulter Corporation, Miami, FL, U.S.A.). The machine was optimized daily using standard Flow Check fluorescence beads (Coulter Corporation), and linearity was checked by Quantum25 beads (Flow Cytometry Standards Corp, San Juan, PR, U.S.A.). Ten thousand events per sample were collected into listmode files and analyzed by the WINMDI 2.8 analysis software (Purdue University, West Lafayette, Indiana, USA). The DC analysis was gated to the standard forward scatter and side scatter profile for large cells.
Mixed lymphocyte reaction. In vitro-generated DCs were washed with PBS, counted, resuspened at different concentration, and irradiated (30 Gy). Allogeneic cord blood CD3 ϩ T cells (1 ϫ 10 5 responder cells/wells) were cultured in triplicate in a 96-well flat-bottom microplate with different numbers of stimulator DCs (DC-to-T cell ratios were 1:1000, 1:100, and 1:10). Cultures were maintained in a humidified atmosphere at 37°C and 5% CO 2 . Twenty microliters of bromodeoxyuridine (BrdU 100 M) was added into the wells 16 -18 h before the 106 end of 5 d culture, and its incorporation was then measured by Cell Proliferation ELISA, BrdU (colorimetric) kit (Roche Molecular Biochemicals, Mannheim, Germany).
IL-12p70, IL-10, and TNF-␣ production by DCs. After 7 d culture, the supernatants of non-BCG-treated and BCG-treated DCs were harvested and stored at Ϫ20°C. The levels of IL-12p70, IL-10, and TNF-␣ in supernatants of non-BCGtreated and BCG-treated DCs were measured by ELISA kits (R&D Systems Inc). The detection ranges of IL-12p70, IL-10, and TNF-␣ were 7.8 -500 pg/mL, 62.5-4000 pg/mL, and 15.6 -1000 pg/mL, respectively.
Cocultures of non-BCG-treated DCs or BCG-treated DCs with cord blood naïve CD4
؉ T cells. Freshly isolated cord blood naïve CD4 ϩ T cells were cocultured with non-BCGtreated cord blood DCs or BCG-treated cord blood DCs (DCto-T cell ratio was 1:10) for 7 d. Supernatants were harvested and stored at Ϫ20°C. The concentrations of IL-4, IL-10, and IFN-␥ in the supernatants were assayed by ELISA kit (R&D Systems Inc). The detection ranges of IL-4, IL-10, and IFN-␥ were 31.2-2000 pg/mL, 62.5-4000 pg/mL, and 15.6 -1000 pg/mL, respectively.
Effects of HSP65 on cord blood monocyte-derived DC maturation. Different concentrations of HSP65 (10, 100, and 1000 ng/mL, Calbiochem, San Diego, CA, U.S.A.) were added after d 5 of culture with IL-4 ϩ GM-CSF for 2 more days. The phenotypic analysis of DCs was performed by flow cytometry.
Neutralization of TNF-␣ in DC cultures. Mature DCs are known to produce high levels of TNF-␣. To determine whether TNF-␣ played a role in mediating the effects of BCG, neutralizing antibodies for TNF-␣ (R&D Systems Inc) at 10 g/mL were added to the CD14 ϩ cell culture on d 5 together with BCG and cultured for 2 more days. The phenotypic analysis of DCs was performed by flow cytometry.
Preparation of protein extracts and Western blot. Nuclear and cytosolic protein extracts from all cells were prepared according to Schreiber et al. (25) . Protein concentrations were determined by a Coomassie Plus Protein Assay Reagent kit (Pierce, Rockford, IL, U.S.A.). For Western blot assays, 5 g of nuclear protein and 30 g of cytosolic protein were separated on 8% to 12% SDS-polyacrylamide gels and electrophoretically transferred to nitrocellulose membranes. The following polyclonal antibodies were used for immunodetection: anti-NFB p65 and anti-IB ␣ (Calbiochem), and anti-RelB and anti-IB ␤ (Santa Cruz Biotechnology, Santa Cruz, CA, U.S.A.).
Statistical analysis. All data were expressed as mean Ϯ SEM. To determine difference between two groups, the paired t test or nonparametric test was used.
RESULTS
BCG promoted cord blood DC maturation by upregulation of MHC class II and costimulatory molecules and down-regulation of MR. We investigated whether BCG could promote cord blood monocyte-derived DC phenotype maturation as reported in adult blood. In cord blood monocyte-derived DCs, there was no difference in the percentages of CD11c ϩ and CD1a ϩ cells between the non-BCG-treated and BCG-treated cord blood DCs. The percentage of MR ϩ cells in BCG-treated cord blood DCs was significantly lower than that in non-BCGtreated DCs (Fig. 1) . Compared with non-BCG-treated cord blood DCs, BCG-treated cord blood DCs were found to have significantly increased intensity in the expression of CD80, CD83, CD86, CD40, and MHC class II (Fig. 2) .
BCG-treated cord blood DCs significantly increased MLR. Freshly harvested cord blood DCs were investigated for their ability to stimulate the proliferation of allogeneic cord blood CD3 ϩ T cells in MLR. Background BrdU uptake by either CD3 ϩ T cells (1 ϫ 10 5 ) or irradiated monocyte-derived DCs (1 ϫ 10 4 ) alone was undetectable. Compared with non-BCGtreated cord blood DCs, BCG-treated cord blood DCs had a higher ability to stimulate CD3 ϩ T cells at DC-to-T ratio of 1:10 (non-BCG-treated DCs, 0.37 Ϯ 0.07; BCG-treated DCs, 0.61 Ϯ 0.08; n ϭ 9; p Ͻ 0.0001; Fig. 3 ).
Comparing the phenotypic maturation between cord blood DCs and adult blood DCs treated by BCG. When normalized to the respective expression levels of non-BCG-treated DCs, the relative expression levels of MR, CD83, CD40, and MHC class II for cord blood and adult blood DCs were not significantly different (Fig. 4) .
Both BCG-treated cord blood DCs and adult blood DCs produced high levels of IL-10 and TNF-␣ but not IL-12p70. To evaluate the ability of cytokine production induced by BCG, we compared the IL-12p70, IL-10, and TNF-␣ levels between cord blood DCs and adult blood DCs. The levels of IL-10 and TNF-␣ were similar in non-BCG-treated cord blood and adult blood DCs. BCG induced high levels of IL-10 and TNF-␣ production from cord blood and adult blood DCs, but no differences were found between the two groups (Fig. 5) . IL-12p70 production was not detected in cord blood and adult blood DCs whether treated with BCG or not.
Cord blood DCs induced naïve CD4 ؉ T cells to produce high levels of IL-10 and medium levels of IFN-␥ but little 
EFFECTS OF BCG ON CB MONOCYTE-DERIVED DC
IL-4.
To investigate the ability of BCG-treated cord blood DCs to skew naïve CD4 ϩ T cell polarization to Th1 or Th2, we measured the levels of IL-4, IL-10, and IFN-␥ production from naïve CD4 ϩ T cells after priming by either non-BCG-treated or BCG-treated cord blood DCs for 7 d. The level of IL-4 production was very low for both (data not shown). Compared with non-BCG-treated cord blood DCs, BCG-treated cord blood DCs did not significantly down-regulate IL-10 and upregulate IFN-␥ production from naïve CD4 ϩ T cells (Fig. 6 ). HSP65 had no effect on cord blood monocyte-derived DC maturation. To investigate for the active component of BCG responsible for promoting DC maturation, we have substituted HSP65 for BCG in our experimental system. HSP65 is a 65-kD member of the heat shock protein family, which has been identified as the immunodominant antigen in mycobacterial diseases (26, 27) . In our system, HSP65 at three different concentrations had no effect on MR, CD86, and MHC class II expression of immature DCs (Fig. 7) .
Anti-TNF-␣ partially neutralized maturation effects of BCG on cord blood monocyte-derived DCs. Anti-TNF-␣ (10 g/mL) partially neutralized the maturation effects of BCG on the down-regulation of MR and up-regulation of CD83 and Relative expression levels of MR, CD83, CD40, and MHC class II molecules on BCG-treated cord blood and adult blood DCs. For the non-BCGtreated cord blood DCs, the expression level of MR was 69% (n ϭ 15); CD83 was 16 Ϯ 3 MFL (n ϭ 11); CD40 was 14 Ϯ 6 MFL (n ϭ 8); and MHC class II was 282 Ϯ 56 MFL (n ϭ 10). For non-BCG-treated adult blood DCs, the expression level of MR was 72 Ϯ 7% (n ϭ 7); CD83 was 17 Ϯ 5 MFL (n ϭ 5); CD40 was 57 Ϯ 25 MFL (n ϭ 5); and MHC class II was 308 Ϯ 48 MFL (n ϭ 6). After BCG treatment, the relative down-regulation of MR and up-regulation of CD83, CD40, and MHC class II molecules was similar between cord blood DCs and adult blood DCs. Results are shown as mean Ϯ SEM.
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MHC class II expression. However, it did not neutralize the effects of BCG on the up-regulation of CD86 and CD40 expression (Fig. 8) .
Generation of mature DCs by BCG led to up-regulation of nuclear Rel-B and down-regulation of cytosolic Rel-B. In immunoblot assays using nuclear protein extracts from purified monocytes, non-BCG-treated DCs and BCG-treated DCs, the expression levels of p65/Rel-A and nuclear Rel-B were significantly higher in both non-BCG-treated DCs and BCG-treated DCs than purified monocytes (Fig. 9) . The expression of p65/Rel-A in non-BCG-treated DCs and BCG-treated DCs was similar, but there was a striking increase in the expression of nuclear Rel-B in BCG-treated DCs accompanied with corresponding down-regulation of the cytosolic Rel-B expression (Fig. 9) .
Maturation of BCG-treated DCs was associated with the degradation of IB ␣ and ␤ in the cytoplasm. The inducible degradation of IBs is crucial for NF-B activation. We investigated whether the increase in the nuclear concentrations of Rel proteins during DC maturation induced by BCG might be mediated through a sustained degradation of IBs, which is critical for NF-B activation. Western blot analysis of cytosolic proteins showed that the concentrations of IB ␣ and ␤ Figure 5 . IL-10 and TNF-␣ production by non-BCG-treated and BCGtreated DCs from cord blood and adult blood. BCG induced significant production of IL-10 and TNF-␣ from cord blood DCs (n ϭ 3, 9) and adult blood DCs (n ϭ 5, 9), but no significant difference was detected between cord blood and adult blood DCs. Results are shown as mean Ϯ SEM. 
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were increased in non-BCG-treated DCs, and both IB ␣ and ␤ were degraded with further maturation induced by BCG (Fig.  9) .
DISCUSSION
As one of the first antigenic challenges for millions of neonates in developing countries, BCG vaccination has been considered to promote Th1 development of the neonatal immune system (20) . Even though the mechanism involved is unclear, it is likely to be dependent on activation of DCs. To clarify the mechanism of BCG on neonatal immunity, we investigated the effects of BCG on cord blood monocytederived DCs and the interaction of BCG-treated cord blood DCs and naïve CD4 ϩ T cells in vitro. First, our results showed that BCG could promote cord blood monocyte-derived DC maturation with up-regulated expression of CD83, CD40, and MHC class II and down-regulated expression of MR. Furthermore, the ability of BCG-treated cord blood DCs to stimulate CD3 ϩ T cell proliferation as revealed by MLR was significantly higher than that of non-BCG-treated cord blood DCs.
Comparing the effects of BCG on cord blood and adult blood DCs, the up-regulated levels of CD83, CD40, and MHC class II and the down-regulated level of MR induced by BCG were similar for both neonates and adults. In our system, BCG could significantly augment the production of TNF-␣ and IL-10, but not IL-12p70 secretion from both cord blood monocytederived DCs and adult blood monocyte-derived DCs. These results indicated that BCG was efficient in inducing maturation of both cord blood and adult blood monocyte-derived DCs.
It has been well known that mycobacterial or BCG infection of DCs results in the up-regulation of proinflammatory cytokines such as IL-1, IL-6, and TNF-␣ and regulatory cytokine IL-12 (13) (14) (15) . These cytokines play a major role in the protective immunity against mycobacterial infection, because they contribute to delayed hypersensitivity. In mice, it has been reported that IL-12 production is crucial to the development of protective immunity against M. tuberculosis (28, 29). Because IL-10 has been shown to inhibit IL-12 production (30) and neutralization of IL-10 restores IL-12 secretion from mycobacterial-infected monocyte-derived macrophages (31) , no production of IL-12p70 from cord blood and adult blood DCs induced by BCG in our study might be related to high levels of IL-10 production induced by BCG. The mechanism of no IL-12p70 production from BCG-treated DCs needs to be studied further.
The ability to prime naïve CD4 ϩ T cells constitutes a unique and critical function of DCs (1) . DC subsets may provide T cells with different cytokines that determine the classes of immune response, such as type 1 versus type 2 CD4 ϩ helper cell profile. In humans, monocyte-derived CD11c ϩ DCs polarize naïve T cells predominantly toward a Th1 profile, whereas the CD11c Ϫ DCs induce T cells to a predominantly Th2 response (32) . However, the extent of polarization by these cells may differ according to their method of isolation and maturation (33) , the ratio of DCs to T cells (34) , or the duration of DC activation (35) . In our experiments, we used monocyte-derived DCs, which phenotypically and functionally belong to DC1, at a ratio of 1:10 (DC:T), which should favor Th1 development (33, 34) . However, after priming with non-BCG-treated or BCG-treated cord blood DCs for 7 d, cord blood naïve CD4 ϩ T cells produced high levels of IL-10, medium levels of IFN-␥, and little IL-4, resembling the cytokine profile of regulatory T cells (Tr1) (36 -38) . Different from immature non-BCG treated DCs, BCG-treated DCs were phenotypically mature, had high allogeneic antigen presentation capacity, and released high levels of TNF-␣. Yet, unlike typical mature DC1, they released high levels of IL-10 and 110 maintain T cells as Tr1. These special properties render BCGtreated DCs more suitable than immature DCs for induction of tolerance. Moreover, this ability for BCG-treated DCs to maintain T cells as Tr1 may explain the negative association of BCG vaccination with atopy development. It opened up the possibility of using BCG-treated DCs for therapeutic intervention of atopy and other allergic diseases.
Mycobacterial HSP65, which has been identified as the immunodominant antigen in mycobacterial diseases that can confer protection equal to that from live BCG vaccine in mice, is a candidate vaccine against tuberculosis (39) . In our system, even high concentrations of HSP65 (up to 1000 ng/mL) had no effect on CD86, MHC class II, and MR expression in cord blood monocyte-derived DCs. These results implied that the effects of BCG on the maturation of cord blood monocytederived DCs is either not mediated through HSP65 or that HSP65 has to be packaged in the context of BCG for its immunogenicity when presented to monocyte-derived DCs (40) .
NF-B is a family of dimers composed of any of the five mammalian Rel proteins (p65/Rel-A, c-Rel, Rel-B, p50/NF-B1, and p52/NF-B2), which are structurally characterized by the Rel homology domain (41, 42) . The Rel homology domain mediates important functions, such as specific DNA binding, nuclear translocation, and protein-protein interactions. The nuclear translocation and activity of NF-B factors are controlled by a family of cytosolic inhibitory proteins, the IBs (43, 44) . Many external stimuli lead to a site-specific phosphorylation of IBs followed by their proteolytic degradation and release of active NF-B, which is then translocated into the nucleus (45) . The genes controlled by NF-B factors encode proteins of principal importance for the immune system, such as MHC I and II molecules, cytokines and their receptors, or cell adhesion molecules. Most of these proteins are also synthesized by DCs and up-regulated with DC maturation. It is known that nuclear Rel-B plays a critical role in DC maturation (7, 8, 10) . Neumann et al. (10) reported that monocyteconditioned medium or cytokines induced maturation of DCs and resulted in an increase in nuclear Rel-B, p50, p52, and c-Rel. This up-regulation of NF-B factors did not correlate with lower levels of cytosolic IBs (10) . In contrast, we demonstrated that in the BCG-induced maturation of DCs, nuclear Rel-B was strongly up-regulated with cytosolic Rel-B down-regulation, with corresponding degradation of cytosolic IB ␣ and ␤. ⌻his observation indicated Rel-B activation is an important signaling pathway for BCG-induced maturation of DCs.
The mechanism of BCG-induced maturation of DCs seems to differ from that induced by cytokines. In fact, we found that BCG could induce high levels of TNF-␣ production by cord blood monocyte-derived DCs, but anti-TNF-␣ could only partially neutralize the effects of BCG on the up-regulation of CD83 and MHC class II molecules and the down-regulation of MR. Anti-TNF-␣, however, had no significant effect on BCGinduced CD86 and CD40 expression in cord blood DCs. These results suggested that the effects of BCG on CD83 expression of DCs are mediated partially through TNF-␣. Other alternative pathways, such as the Toll-like receptors, which also promote nuclear protein translocation (46) , may also be involved.
CONCLUSIONS
In conclusion, BCG promoted cord blood monocyte-derived DC maturation to a similar extent as adult blood DCs. In the maturation process, nuclear Rel-B up-regulation and cytosolic Rel-B down-regulation were correlated with degradation of cytosolic IB ␣ and ␤. Native HSP65 had no effect on cord blood monocyte-derived DC maturation, whereas anti-TNF-␣ could only partially neutralize the effects of BCG on cord blood DC maturation. Further elucidation of the mechanism of interaction between cord blood DCs and T cells, such as that underlying deficient IL-12p70 production, may lead to a novel strategy for developing a more effective vaccine against M. tuberculosis. In addition, the therapeutic use of BCG-treated DCs worth further exploration.
